The global prefilled syringes market size is anticipated to reach USD 16.73 billion by 2030, expanding at a CAGR of 13.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. Key factors driving the market expansion include technological advancements in auto-injectors and growing usage of prefilled syringes owing to its reduced prices per dose.
The current COVID-19 outbreak is expected to have a substantial impact on the industry. The pandemic has resulted in a significant surge in demand for emergency supplies, medical disposables, medicines, and hospital equipment. According to American Pharmaceutical Review in December 2021, COVID-19 vaccines are being created at an unprecedented rate in response to the worldwide pandemic. COVID-19 vaccination doses totaled 7.3 billion by November 9, 2021, with approximately 30.3 million doses provided daily.
As a result of COVID-19, there has been an increase in the production of COVID-19 vaccines, resulting in increased demand for prefilled syringes. For instance, in March 2022, Schott announced further investments in its pharma sector, including expanding its capacity in Hungary for prefillable glass syringe production. The increased capacity is likely to benefit the global market and provide greater supply security for major pharmaceutical corporations and contract manufacturing firms. As a result, due to the outbreak of coronavirus infection in 2020, sales of prefilled syringes increased globally.
Furthermore, emergency syringes used to treat some of COVID-19's most significant side effects such as heart damage have historically been scarce. Despite the heightened demand during the outbreak, manufacturers provide various programs that identifies high-quality, protected supply bases for medications that are or could be added to the national drug scarcity list. For instance, in October 2019, Premier Inc. teamed up with Amphastar Pharmaceuticals, Inc. to provide phytonadione injection and emergency, pre-filled syringes of sulphate, dextrose, sodium bicarbonate, epinephrine, atropine, calcium chloride, and lidocaine to healthcare practitioners through its ProvideGx programme. These characteristics are projected to generate lucrative market growth prospects.
Request a free sample copy or view report summary: Prefilled Syringes Market Report
The disposable segment accounted for the largest market share of 91.4% in 2023 and is expected to register the fastest CAGR over the forecast period.
The glass segment accounted for the largest share of 51.4% in 2023. The glass acts as a strong barrier against external elements like moisture, oxygen, and light.
The vaccines and immunizations segment accounted for the largest share of 25.8% in 2023. Numerous vaccines require multiple doses to be administered over a period of time.
The Europe prefilled syringes market dominated the global market and is driven by the strong preference of medical professionals for injectable devices that are prefilled to reduce damage caused by needles.
Grand View Research has segmented the global prefilled syringes market on the basis of type, material, application, distribution channel, and region:
Prefilled Syringes Type Outlook (Revenue, USD Million, 2018 - 2030)
Disposable
Reusable
Prefilled Syringes Material Outlook (Revenue, USD Million, 2018 - 2030)
Glass
Plastic
Prefilled Syringes Application Outlook (Revenue, USD Million, 2018 - 2030)
Vaccines & Immunizations
Anaphylaxis
Rheumatoid Arthritis
Diabetes
Autoimmune Diseases
Oncology
Others
Prefilled Syringes Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Mail Order Pharmacies
Ambulatory Surgery Centers
Prefilled Syringes Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Prefilled Syringes Market
BD
Gerresheimer AG
SCHOTT Pharma AG
Stevanato Group
Nipro Corporation
Terumo
West pharmaceuticals
Fresenius
Catalent
Aptar Pharma
"The quality of research they have done for us has been excellent..."